

Curriculum Vitae

Hamid Reza Rasekh

Permanent Address

Apt 4C, Bldg 18, Sina
Residential Complex, Iran
Zamin Ave, Shahrak Gharb
Tehran, Iran,

Work Address

School of Pharmacy Shahid.
Beheshti Univ. of Medical
Sciences Vali-Asr Ave. and
Niyayesh HWY Junction,
Tehran, Iran
P.O. Box1996835113

Marital Status

Married
Two Children

E-Mail: hrasekh@gmail.com
Phone:+98-21-88665692
Fax : +98-21-88665692

Academic Background

1994 -1995 Post-Doctoral Training, Neuropharmacology Lab, College of
Pharmacy and Pharmaceutical Sciences, Florida A&M
University.
1990 - 1994 Ph.D., Pharmacology and Toxicology, Florida A&M University.
1987 - 1990 M.S., Pharmaceutical Sciences, Florida A&M University, Tallahassee,
FL, USA
1981 - 1985 B.S., Toxicology, Northeast Louisiana University, Monroe, LA., USA
1980 High School Diploma, Grant Union High School, Sacramento, CA., USA

Academic and Research Positions

2013 – Present Professor, Dept of Pharmacology and Toxicology, School of Pharmacy,
Shahid Beheshti Univ. of Medical Sciences, Tehran, Iran
2014 – Present Chairman of the Board, Zahravi Pharmaceutical Company, Tehran, Iran
2009 – 2017 Head, Dept. of Pharmacoeconomics and Pharma Management, School
of Pharmacy, Shahid Beheshti Univ. of Medical Sciences, Tehran, Iran
2016 - 2017 Member of the Board, Pharma Chemie Company, Tehran, Iran
2014 – 2015 Member of the Board, Farayand Gostar Chemical Company, Tehran,
Iran

2012 – 2014 Vice President – Active Pharmaceutical Ingredients – Tamin Pharmaceutical Investment Company, Tehran, Iran

2008 – 2014 Member of the Board, Darou-Pakhsh Pharmaceutical Manufacturing Company, Tehran, Iran.

2010 – 2012 Member of the Board, KBC Pharmaceutical Company, Tehran, Iran

2007 – 2011 Member of the Board, Pharma Chemie Pharmaceutical Company, Tehran, Iran.

2006 – 2009 Senior Advisor, Deputy Minister for Food and Drug, Ministry of Health and Medical Education, Tehran, Iran

2006 – 2007 Advisor, Planning and Development, Medical Procurement Organization, Iranian Red Crescent Society, Tehran, Iran

2005 – 2006 Director General, Division of Pharmaceutical and Narcotic Affairs, Ministry of Health and Medical Education, Tehran, Iran

2003 - 2005 Vice-President, Business Development and Strategic Planning, Darou Pakhsh Pharmaceutical Manufacturing Company, Tehran, Iran

2001 – 2003 Vice-President, Research and Development, Tolid-Darou Pharmaceutical Company, Tehran, Iran

1995 – 2001 Advisor, Drug Abuse and Addiction, Presidential Office of Technology Cooperations, Tehran, Iran

1998 – 2002 Founder and Director, Drug and Poison Information Center, Shahid Beheshti Univ. of Medical Sciences, Tehran, Iran

1997 – 2001 Assistant Dean in Finance and Administration, School of Pharmacy, Shahid Beheshti Univ. of Medical Sciences, Tehran, Iran

1996 - 1998 Head, Dept. of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti Univ. of Medical Sciences, Tehran, Iran

1993 Research Intern, Psychiatric Disorders, Pharmacology Dept., Parke-Davis Pharmaceutical Company, Ann Arbor, MI., U.S.A.
Assessment of toxic effects of pharmaceuticals on Dopaminergic system of brain.

1992 - 1993 Instructor, Introduction to Natural Sciences, TRIO Lab, Florida A&M University, Tallahassee, FL. U.S.A.

- 1992 Assistant, Medline Search, College of Pharmacy, Florida A&M University.
Train faculties, students, and medical professionals on the use of computer search by Grateful Med, Medline, and Toxline.
- 1992 Research Intern, Toxicology/Pathology Department, 3M Pharmaceuticals, St. Paul, MN. U.S.A.
Pathological assessment of potential drugs for the immune system using immunohistochemistry.
- 1992 Graduate Assistant, Biostatistics, College of Pharmacy, Florida A&M University.
Conduct lecture and help sessions for pharmacy students.
- 1990 Research Intern, Pulmonary Drug Delivery Lab, Biosciences Division, 3M Company, St. Paul, MN. U.S.A.
Assessment of Pharmacological and Toxicological Aspects of administration of various agents via pulmonary route.

Extracurricular Courses

- 1995 Basic Applications in Risk Assessment, Society of Toxicology.
- 1995 Basic Molecular Methods for the Analysis of Gene Regulation and Expression, Society of Toxicology.
- 1990 Environmental Video Teleconference on Newest Analytical Methods and Techniques, Environmental Protection Agency.
- 1989 Mid-America Course in Toxicology, University of Kansas Medical Center
- 1986 Developmental Toxicology for the General Toxicologist, Society of Toxicology.
- 1986 Use of Innovative Methodology in Toxicology, Society of Toxicology.

Memberships, Achievements, and Awards

- Member, International Federation of Pharmaceutics (FIP), 2002
- Member, International Society of Pharmacoeconomics and Outcome Research (ISPOR), 2002
- Member, National Board of Toxicology, Ministry of Health and Medical Education.(1996-2005)
- Member, American Association for Advancement of Science, 2001
- Head, National Board of Toxicology, Ministry of Health and Medical Education, 1999
- Executive Member, Iranian Association of Toxicology, 1998
- Member, Iranian Association of Pharmacology and Physiology, 1997
- Member, Association of European Toxicologists, Eurotox, 1996
- Member, Society for Neuroscience, U.S.A., 1995
- Research Achievement Scholarship, 3M Company, U.S.A., 1994

Research Achievement Scholarship, 3M Company, 1993
Student Member, Society of Toxicology, U.S.A., 1993
Research Achievement Scholarship, 3M Company, 1992
Research Achievement Scholarship, 3M Company, 1991
Research Achievement Award, Florida A&M University, U.S.A., 1988
Member, Rho Chi Pharmaceutical Honor Society, U.S.A., 1988

Research Techniques and Experiences

Pharmacological and Toxicological Screening of synthetic and natural products
Drug Utilization Review (DUR) studies of Narcotics and Antiinfectives
Epidemiological studies of Opioid use and abuse
Jugular vein and carotid artery catheterization in rats and rabbits
Metabolic aspects of selenium toxicity
Analytical techniques using radioimmunoassay
Analysis of mediators of glucoregulation
Development of an anesthetic procedure for rabbits (5-hour anesthesia)
Assessment of neurochemical and behavioral changes in the CNS
Brain microdialysis in rats
Analysis of neurotransmitters in CNS using HPLC-ECD
Applications of softwares (both IBM and Macintosh) in health sciences

Teaching Experiences:

- **Responsible for Launching the first Pharmaceutical MBA and DBA Programs in Iran**

General Courses (Pharm.D. and B.S. Level)

Pharmacy Management
General Toxicology
Computer Applications in Medical Sciences
General Pharmacology (Opioids, Endocrine, and Non-steroidal Anti-inflammatory Drugs)
Experimental Design

Advanced Courses (Ph.D. Level)

Pharmaceutical Policy
Pharmaceutical Management
Pharmacoeconomics
Advanced Toxicology
Pharmacotherapy of Drug Abuse and Addiction
Introduction to Research
Drug and Poison Information Techniques
Analytical Toxicology (RIA and Isolation of Biological Samples)
Receptor Pharmacology (Dopaminergic System)

Full Papers:

1. J.Shirmohammsdi, Shahriar Azizi, HR.Rasekh, F.Peiravian, M.Polroudi Moghaddam (2023) Investigating the Relationship between the Market Orientation Approach of Pharmaceutical Companies and their Innovative Performance: The Mediating Role of Dynamic Capabilities and Corporate Social Responsibility. **Iranian journal of pharmaceutical research: IJPR**. 22
2. Sajjad Esmaeili¹, Mehdi Azimi¹, Fatemeh Babaei¹, Hamidreza Rasekh(2022) Measuring the Education Status, Skills, and Jobs of the Ph.D postgraduates in Shahid Beheshti school of Pharmacy. *۱۴۰۲ تابستان، ۲۰ شماره، ۱۴ دوره پزشکی، علوم آموزش توسعه افق مجله*
3. ZK Majd, M Peikanpour, SM Ghasemi, S Esmaeili, H Rasekh, R Sadeghi, ... (2021) Use Pattern of Personal Care Products: A Cross-Sectional National Survey. **International Pharmacy Acta**. 5 (1), e12: 1-14
4. M Ekhlasi, M Peikanpour, H Rasekh. (2021) Explaining the Possible Achievements and Consequences of Various Exchange Rate Policies in Pharmaceutical Sector: A Qualitative Study. **Iranian Journal of Health Insurance**. 4 (2), 118-127
5. S Esmaeili, S Omid-Malayeri, H Hajimehdipoor, HR Rasekh, HR Moghimi, ... (2020) The role of lecithin on topical anti-inflammatory activity of turmeric (*Curcuma longa* L.) ointment. **Journal of Medicinal Plants**. 19 (76), 89-98
6. A Jelodari, Z Sharif, HR Rasekh, N Yousefi (2020) Case Study of the Historical Experience of Opium Harm Reduction Using Controlled Supply Chain in Iran. **HAKIM RESEARCH JOURNAL** 23 (188), 74-85.
7. A Jelodari, Z Sharif, HR Rasekh, N Yousefi (2020) Case Study of the Historical Experience of Opium Harm Reduction Using Controlled Supply Chain in Iran. **HAKIM RESEARCH JOURNAL**. 23 (188), 74-85
8. A Moosivand, AR Ghatari, HR Rasekh (2019) Supply chain challenges in pharmaceutical manufacturing companies: using qualitative system dynamics methodology. **Iranian journal of pharmaceutical research: IJPR**. 18 (2), 1103
9. F Rahimi, HR Rasekh, E Abbasian, F Peiravian (2018) A new approach to pharmaceutical pricing based on patients' willingness to pay **Tropical Medicine & International Health** 23 (12), 1326-1331.
10. M Peikanpour, S Esmaeli, N Yousefi, A Aryaeinezhad, H Rasekh (2018) A review of achievements and challenges of Iran's health transformation plan. **Payesh (Health Monitor)** 17 (5), 481-494

11. M Peikanpour, S Esmaeli, N Yousefi, A Aryaeinezhad, HR Rasekh (2018) Php200-a Review of achievements and challenges of Iran'S health transformation plan. **Value in Health** 21, S184
12. F Rahimi, H Rasekh, F Peiravian, E Abbasian (2018) Using discrete choice experiment to determine willingness to pay for medicine interferon-beta by multiple sclerosis patients. **Iranian Journal of Pharmaceutical Sciences** 14 (4), 71-78
13. F Rahimi, H Rasekh, E Abbasian, F Peiravian (2018) Selecting reference countries in external reference based pricing: The case study of Iran. **Iranian Journal of Pharmaceutical Sciences** 14 (3), 36-48
14. Seydi E, Salimi A, Rasekh HR, Mohsenifar Z, Pourahmad J. (2018) Selective Cytotoxicity of Luteolin and Kaempferol on Cancerous Hepatocytes Obtained from Rat Model of Hepatocellular Carcinoma: Involvement of ROS-Mediated Mitochondrial Targeting. **Nutrition and cancer**. 19;70(4):594-604.
15. Rahimi F, Rasekh HR, Abbasian E, Peiravian F, Etemadifar M, Ashtari F, (2018) Sabzghabae AM, Amirsadri MR. Patient preferences for Interferon-beta in Iran: A discrete choice experiment. **PloS one**. 28;13(3)
16. Rahimi F, Rasekh HR, Peiravian F. (2017) Patient Preferences for Interferon-Beta in Iran: A Discrete Choice Experiment. . **PloS one Value in Health**. 1;20(9):A726.
17. Farahani AV, Salamzadeh J, Rasekh HR, Najafi S, Mosadegh V. (2018) The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran). **Iranian Journal of Pharmaceutical Research: IJPR**.;17(Suppl):64.
18. Yousefi N, Mehralian G, Rasekh HR, Yousefi M. (2017) New Product Development in the Pharmaceutical Industry: Evidence from a generic market. **Iranian journal of pharmaceutical research: IJPR**.;16(2):834.
19. Mehralian G, Nazari JA, Nooriparto G, Rasekh HR. (2017) TQM and organizational performance using the balanced scorecard approach. **International Journal of Productivity and Performance Management**. 9;66(1):111-25.
20. Mehralian G, Nazari JA, Zarei L, Rasekh HR. (2016) The effects of corporate social responsibility on organizational performance in the Iranian pharmaceutical industry: The mediating role of TQM. **Journal of cleaner production**. 1;135:689-98.
21. Seydi E, Rasekh HR, Salimi A, Mohsenifar Z, Pourahmad J. (2016) Myricetin selectively induces apoptosis on cancerous hepatocytes by directly targeting their mitochondria. **Basic & clinical pharmacology & toxicology**.;119(3):249-58.
22. Mehralian Gh, Nazari J, Rasekh HR, Hosseini S, (2016) "TOPSIS approach to prioritize critical success factors of TQM: Evidence from the pharmaceutical industry", **The TQM Journal**, Vol. 28 Issue: 2, pp.235-249, <https://doi.org/10.1108/TQM-03-2014-0028>

23. Yousefi N, Mehralian GH, Rasekh HR, Tayeba H, (2016) Pharmaceutical Innovation and Market Share: evidence from a generic market, **International Journal of pharmaceutical and Healthcare**, 10 (4), 376-389
24. Golestani M, Eshghi P, Rasekh HR, et al, (2016) Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to treat Hemophilia A Patients with Inhibitors in Iran, **Iranian Journal of Pharmaceutical Research**, Available Online from 25 May 2016
25. Mehralian GH, Nazari JA, Rasekh HR, Hosseini S (2016) TOPSIS approach to prioritize critical success factors of TQM: Evidence from the pharmaceutical industry, **The TQM Journal**, 28(2): 235-249
26. Viyanchi A; Rajabzadeh Ghatari A; Rasekh HR; Safi-khani HR (2016) Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran- TOPSIS-Based Consensus Model, **Iranian Journal of Pharmaceutical Research**, 15 (1): 369-381
27. Seyedifar M, Nikfar S, Abdollahi-Asl A, Rasekh HR, and Ehsani A (2015) An Rasekh HR, Rajabzadeh Ghatari A, SafiKhani HR (2015) Selecting the acceptance criteria of medicines in the reimbursement list of public health insurance of Iran, using the “Borda” method: a pilot study, **Iranian Journal of Pharmaceutical Research** 14 (4): 1306-1316
28. Viyanchi, A, Rasekh HR, Rajabzadeh Ghatari A, SafiKhani HR (2015) Selecting the acceptance criteria of medicines in the reimbursement list of public health insurance of Iran, using the “Borda” method: a pilot study, **Iranian Journal of Pharmaceutical Research** 14 (4): 1306-1316
29. Viyanchi A, Rasekh HR, Rajabzadeh Ghatari A, SafiKhani HR (2015) Drug insurance coverage in Iran and some selected countries: a comparative study. **Journal of Health Administration** (JHA) 18 (60): 7
30. Khatibi M and Rasekh HR (2015) - Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran, **Iranian Journal of Pharmaceutical Research** 14 (2): 635
31. Mehralian Gh, Nazari JA, Rasekh HR, (2014) Exploring the relationship between the knowledge creation process and intellectual capital in the pharmaceutical industry, **The current issue and full text archive of this journal is a vailable at** www.emeraldinsigh.com/0969-6474.htm
32. Mehralian Gh, Rangchian M, Rasekh HR, (2014) Client priorities and satisfaction with community pharmacies: the situation in Tehran, **International Journal of Clinical Pharmacy** 36 (4): 707-715

33. Shabaninejad H, Mehralian Gh, Rashidian A, Baratimarnani A, Rasekh HR, (2014) Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market, **Daru journal of pharmaceutical sciences**.
34. Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Imani A, (2014) Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients with Haemophilia and Inhibitors, **Iran Red Crescent Med J** 16(12):e24551
35. Foroughi Moghadam MJ, Peiravian F, Naderi A, Rajabzadeh A, Rasekh HR, (2014) An Analysis of Job Satisfaction among Iranian Pharmacists through Various Job Characteristics, **Iranian Journal of Pharmaceutical Research** 13 (3): 1087-1096
36. Peiravian F, Rasekh HR, Jahani Hashemi H, Mohammadi N, Jafari N (2013) Drug Literacy in Iran: the Experience of Using “The Single Item Health Literacy Screening (SILS) Tool”, , **Iranian Journal of Pharmaceutical Research** 13 (supplement): 217-224
37. Mehralian G, Rasekh HR, Akhavan P, Sadeh MR, (2012) The Impact of Intellectual Capital Efficiency on Market Value: An Empirical Study from Iranian Pharmaceutical Companies, **Iranian Journal of Pharmaceutical Research**, 11 (1): 195 - 207
38. Mehralian Gh, Rasekh HR, Akhavan P, Farzandy Gh, (2012) An assessment of Structural (organizational) and Relational Capital Indicators in Knowledge- Intensive Industries Evidence from Pharmaceutical Industry, **Journal of Basic and Applied Scientific Research**, 2 (8): 8240 - 8242
39. Rasekh HR, Mehralian Gh, Vatankhah A A, (2012) Situation Analysis of R&D Activities: An Empirical Study from Iranian Pharmaceutical Companies, **IJPR**, 11(4): 1013
40. Imani A, Rasekh HR, Asefzadeh, Salamzadeh J, Haghdoost A A, Golestani M, (2012) Cost Analysis of Disease modifying drugs Therapy for Patients with Multiple Sclerosis in Iran, **American Journal of scientific Research**, 95-102
41. Imani A, Rasekh HR, Asefzadeh, Salamzadeh J, Haghdoost A A, Golestani M, (2012) Cost – Effectiveness Analysis of Interferon β -1a versus Interferon β -1b in the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) in Iran, **Archives Des Sciences**, 65 (8)
42. Mehralian Gh, Rajabzadeh A, Sadeh MR, Rasekh HR, (2012) Intellectual capital and corporate performance in Iranian pharmaceutical industry, **Journal of Intellectual Capital**.
43. Rasekh HR, Imani A, Karimi M, and Golestani M (2011) Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran, **ClinicoEconomics and outcomes research: CEOR** 3, 207

44. Rasekh HR, Hosseinzadeh L, Mehri S, Kamali-Nejad M, Aslani M, Tanbakoosazan F (2011) Safety Assessment of Ocium Bssilicum Hydroalcoholic Extract in Wistar Rats: Acute and Subchronic Toxicity Studies, **Iranian Journal of Basic Medical Sciences**.
45. Rasekh HR, Imani A, Karimi M, Golestani M, (2011) Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran , **Clinico Economics and Outcomes Research**
46. Rezaei M, Rasekh HR, Ahmadiani A, Pourahmad J,(2008) Involvement of Subcellular Organelles in Inflammatory Pain-Induced Oxidative Stress and Apoptosis in the rat Hepatocytes, **Archives of Iranian Medicin, Volume 11. Number 4**
47. Sarahroodi Sh, Rasekh HR, Kamali-nejad M, Mahboobi S, (2008) Golucose lowering effect of the water extract of septum of jugbns regalinn , **Pharmacognosy magazine ISSN**.
48. Rasekh HR, Nazari P, Kamali-Nejad. M, Hosseinzadeh L, (2007) Acute and Subchronic Oral toxicity of Galega officinalis in rats, **Journal of Ethno-Pharmacology**
49. Rasekh HR, Yazdanpanah H, Hossenizadeh L, Bazmohammadi N and Kamalinejad M (2005) Acute and subchronic toxicity of Teucrium polium total extract in rats, **Iranian Journal of Pharmaceutical Research**, 4(4):245-249.
50. Daraei B, Ghazi-Khansari M, and Rasekh HR. (2004) T2 Toxin hepatotoxicity in the in situ rat liver model, **Iranian Journal of Pharmaceutical Research**, 3(4):225-230.
51. Shephard GS, Marasas WF, Yazdanpanah H, Rahimian H, Safavi N, Zarghi A, Shafaati A, and Rasekh HR. (2002)Fumonisin B(1) in maize harvested in Iran during 1999. **Food Additives and Contaminants**, 19(7): 676-9.
52. Rasekh HR, Khoshnood-Mansourkhani MJ, and Kamalinejad M. (2001) Hypolipidemic effects of teucrium polium in rats. **Fitoterapia**, 72(8): 937-9.
53. Yazdanpanah H, Miraglia M, Calfapietra FR, Brera Carlo B, and Rasekh HR(2001) Natural occurrence of mycotoxins in cereals from Mazandaran and Golestan provinces. **Archives of Iranian Medicine**, 4(3): 104-114.
54. Jamshidzadeh A, Aminlari M, and Rasekh HR. (2001) Rhodanese and arginase activity in normal and cancerous tissues of human breast, esophagus, stomach and lung, **Archives of Iranian Medicine**, 4(2):88-92.

55. Yazdanpanah H, Roshanzamir F, Shafaghi B, Faizi M, Elhami M, Rasekh HR. (1997) Assessment of possible protective roles of selenium, zinc, and cis-stilbene oxide against acute T-2 toxin poisoning: a preliminary report. **Natural Toxins**, 5(4): 133-5.
56. Rasekh HR, Davis MD, Cooke LW, Mazzio EA, Reams RR, and Soliman KFA, (1997) Effect of selenium on central dopaminergic system: a microdialysis study, **Life Sciences** 61(11):1029-1035.
57. Yazdanpanah H, Roshanzamir F, Shafaghi B, Faizi M, Elhami M, and Rasekh HR, (1997) Assessment of possible protective roles of selenium, zinc, and cis-stilbene oxide against T-2 toxin poisoning: A preliminary report, **Natural Toxins**, 5(4): 133-35.
58. Curtis SL, Nonavinakere VK, Potmis RA, Rasekh HR, Remas R, and Early JL, (1996) Subacute exposure to cadmium chloride induces HSP-72 in rat liver, **Research Communications in Molecular Pathology and Pharmacology**, 94(2):221-4.
59. Nonavinakere VK, Potmis RA, Rasekh HR, Bell RR, and Early JL, (1993) Selenium Lethality: Role of glutathione and metallothionein, **Toxicology Letters**, 66:273-279.
60. Potmis RA, Nonavinakere VK, Rasekh HR, and Early JL, (1993) Effect of selenium (Se) on plasma ACTH, b-endorphin, corticosterone and glucose in rat: influence of adrenal enucleation and metyrapone pretreatment, **Toxicology**, 79:1-9.
61. Rasekh HR, Potmis RA, Nonavinakere VK, Early JL, and Iszard MB, (1991) Effect of selenium on plasma glucose of rats: role of insulin and glucocorticoids, **Toxicology Letters**, 58:199-207.